The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2025 | CAR-T in CLL: updates from the TRANSCEND-CLL-004 trial and when to choose CAR-T for these patients
Tanya Siddiqi, MD, City of Hope National Medical Center, Duarte, CA, shares updates on the recent approval of CAR-T therapy for patients with chronic lymphocytic leukemia (CLL), commenting on where CAR T-cells may fit into the treatment landscape. Dr Siddiqi references the TRANSCEND-CLL-004 trial (NCT03331198), which evaluated lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory (R/R) CLL. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting in Strasbourg, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
